265 related articles for article (PubMed ID: 35159389)
1. Immune Dysfunction, Cytokine Disruption, and Stromal Changes in Myelodysplastic Syndrome: A Review.
Lynch OF; Calvi LM
Cells; 2022 Feb; 11(3):. PubMed ID: 35159389
[TBL] [Abstract][Full Text] [Related]
2. The bone marrow stem stromal imbalance--a key feature of disease progression in case of myelodysplastic mouse model.
Das M; Chatterjee S; Basak P; Das P; Pereira JA; Dutta RK; Chaklader M; Chaudhuri S; Law S
J Stem Cells; 2010; 5(2):49-64. PubMed ID: 22049615
[TBL] [Abstract][Full Text] [Related]
3. CXCL12+ stromal cells as bone marrow niche for CD34+ hematopoietic cells and their association with disease progression in myelodysplastic syndromes.
Abe-Suzuki S; Kurata M; Abe S; Onishi I; Kirimura S; Nashimoto M; Murayama T; Hidaka M; Kitagawa M
Lab Invest; 2014 Nov; 94(11):1212-23. PubMed ID: 25199050
[TBL] [Abstract][Full Text] [Related]
4. Bone marrow niche in the myelodysplastic syndromes.
Cogle CR; Saki N; Khodadi E; Li J; Shahjahani M; Azizidoost S
Leuk Res; 2015 Oct; 39(10):1020-7. PubMed ID: 26276090
[TBL] [Abstract][Full Text] [Related]
5. Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Kaszuba CM; Rodems BJ; Sharma S; Franco EI; Ashton JM; Calvi LM; Bajaj J
J Vis Exp; 2023 Nov; (201):. PubMed ID: 38009736
[TBL] [Abstract][Full Text] [Related]
6. The microenvironment in myelodysplastic syndromes: Niche-mediated disease initiation and progression.
Li AJ; Calvi LM
Exp Hematol; 2017 Nov; 55():3-18. PubMed ID: 28826860
[TBL] [Abstract][Full Text] [Related]
7. Targeting of the bone marrow microenvironment improves outcome in a murine model of myelodysplastic syndrome.
Balderman SR; Li AJ; Hoffman CM; Frisch BJ; Goodman AN; LaMere MW; Georger MA; Evans AG; Liesveld JL; Becker MW; Calvi LM
Blood; 2016 Feb; 127(5):616-25. PubMed ID: 26637787
[TBL] [Abstract][Full Text] [Related]
8. Biology of the bone marrow microenvironment and myelodysplastic syndromes.
Rankin EB; Narla A; Park JK; Lin S; Sakamoto KM
Mol Genet Metab; 2015; 116(1-2):24-8. PubMed ID: 26210353
[TBL] [Abstract][Full Text] [Related]
9. The immunological role of mesenchymal stromal cells in patients with myelodysplastic syndrome.
Zheng L; Zhang L; Guo Y; Xu X; Liu Z; Yan Z; Fu R
Front Immunol; 2022; 13():1078421. PubMed ID: 36569863
[TBL] [Abstract][Full Text] [Related]
10. Bone marrow niches in myeloid neoplasms.
Kitagawa M; Kurata M; Onishi I; Yamamoto K
Pathol Int; 2020 Feb; 70(2):63-71. PubMed ID: 31709722
[TBL] [Abstract][Full Text] [Related]
11. Inappropriate Notch activity and limited mesenchymal stem cell plasticity in the bone marrow of patients with myelodysplastic syndromes.
Varga G; Kiss J; Várkonyi J; Vas V; Farkas P; Pálóczi K; Uher F
Pathol Oncol Res; 2007; 13(4):311-9. PubMed ID: 18158566
[TBL] [Abstract][Full Text] [Related]
12. Coexistence of aberrant hematopoietic and stromal elements in myelodysplastic syndromes.
Abbas S; Kini A; Srivastava VM; M MT; Nair SC; Abraham A; Mathews V; George B; Kumar S; Venkatraman A; Srivastava A
Blood Cells Mol Dis; 2017 Jul; 66():37-46. PubMed ID: 28822917
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of bone marrow microenvironment could change how myelodysplastic syndromes are diagnosed and treated.
Aanei CM; Catafal LC
Cytometry A; 2018 Jul; 93(9):916-928. PubMed ID: 30211968
[TBL] [Abstract][Full Text] [Related]
14. Stromal abnormalities in neoplastic bone marrow diseases.
Dührsen U; Hossfeld DK
Ann Hematol; 1996 Aug; 73(2):53-70. PubMed ID: 8774614
[TBL] [Abstract][Full Text] [Related]
15. The inflammatory microenvironment in MDS.
Yang L; Qian Y; Eksioglu E; Epling-Burnette PK; Wei S
Cell Mol Life Sci; 2015 May; 72(10):1959-66. PubMed ID: 25662443
[TBL] [Abstract][Full Text] [Related]
16. Beyond the Niche: Myelodysplastic Syndrome Topobiology in the Laboratory and in the Clinic.
Flores-Figueroa E; Gratzinger D
Int J Mol Sci; 2016 Apr; 17(4):553. PubMed ID: 27089321
[TBL] [Abstract][Full Text] [Related]
17. What is the role of the microenvironment in MDS?
Calvi LM; Li AJ; Becker MW
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101113. PubMed ID: 31779976
[TBL] [Abstract][Full Text] [Related]
18. [Cytogenetic characteristics of hematopoietic and stromal progenitor cells in myelodysplastic syndrome].
Pimenova MA; Parovichnikova EN; Kokhno AV; Domracheva EV; Manakova TE; Mal'tseva IuS; Konnova ML; Shishigina LA; Savchenko VG
Ter Arkh; 2013; 85(7):34-42. PubMed ID: 24137945
[TBL] [Abstract][Full Text] [Related]
19. Phenotypic alteration of bone marrow HSC and microenvironmental association in experimentally induced leukemia.
Basak P; Chatterjee S; Das M; Das P; Pereira JA; Dutta RK; Chaklader M; Chaudhuri S; Law S
Curr Stem Cell Res Ther; 2010 Dec; 5(4):379-86. PubMed ID: 20528754
[TBL] [Abstract][Full Text] [Related]
20. De novo AML exhibits greater microenvironment dysregulation compared to AML with myelodysplasia-related changes.
Lopes MR; Pereira JK; de Melo Campos P; Machado-Neto JA; Traina F; Saad ST; Favaro P
Sci Rep; 2017 Jan; 7():40707. PubMed ID: 28084439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
